

The current role and future perspectives of minimally invasive coronary artery bypass grafting

German Alberto Fortunato^{1,2}^, Piroze M. Davierwala^{1,3}

¹Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Canada; ²Department of Cardiovascular Surgery, Italian Hospital of Buenos Aires, Buenos Aires, Argentina; ³Department of Surgery, University of Toronto, Toronto, Canada

Correspondence to: Dr. Piroze M. Davierwala. Director of Minimally Invasive Cardiac Surgery, Peter Munk Cardiac Center, Toronto General Hospital, Toronto, Canada; Associate Professor, Department of Surgery, University of Toronto, Toronto, Canada. Email: pirarm@hotmail.com.

Keywords: Minimally invasive; coronary bypass surgery; overview

Received: 16 October 2022; Accepted: 22 November 2022; Published online: 03 January 2023. doi: 10.21037/jovs-22-41 **View this article at:** https://dx.doi.org/10.21037/jovs-22-41

Coronary artery bypass graft (CABG) surgery performed through a left anterior small thoracotomy (LAST) without utilization of cardiopulmonary bypass (CPB) has become an increasingly popular technique worldwide since the first reports of the use of off-pump techniques and minimally invasive access in CABG surgery were published (1). Constant improvements in the composition of coronary stents and advancements in the techniques of percutaneous coronary intervention (PCI) have been chiefly responsible in inspiring cardiac surgeons to reduce the invasiveness of surgical revascularization techniques, resulting in the development of minimally invasive cardiac surgical (MICS) procedures.

The three main factors of conventional CABG that are predominantly responsible for its invasiveness are the use of CPB, manipulation of the ascending aorta, and sternotomy. Therefore, the essential steps in reducing the invasiveness of CABG surgery would include: (I) avoiding CPB, thereby decreasing the systemic inflammatory response, preventing hemodilution, reducing blood transfusions, and lowering the risk of stroke, neurocognitive disturbances, acute kidney injury, respiratory insufficiency and atrial fibrillation (2). (II) Avoiding aortic manipulation by refraining from partial or total clamping of the ascending aorta does reduce the stroke rate to that observed following PCI (3). (III) Avoiding a sternotomy, which eliminates the risk of sternal wound The present article describes the currently available techniques of minimally invasive coronary surgery in brief, their role in clinical practice today and their potential for changing practice in the future.

Current therapies

Minimally invasive direct coronary artery bypass (MIDCAB)

In the field of coronary surgery, the MIDCAB procedure, which involves the use of the left internal thoracic artery (LITA) to graft the left anterior descending (LAD) artery through a LAST approach has become an excellent alternative to full sternotomy for surgical revascularization for proximal LAD disease. It is probably one of the commonest MICS procedures performed all over the world today (5-7). Following LITA harvest, which is facilitated by specialized retractors, the LITA-LAD anastomosis is

complications irrespective of the presence of risk factors such as diabetes mellitus, chronic obstructive pulmonary disease, use of bilateral internal thoracic arteries (ITAs), steroid use, osteomyelitis etc., facilitates early extubation, thereby reducing respiratory complications and intensive care unit and hospital stay, and quick recovery and return to work and provides better cosmesis as an added benefit (4).

[^] ORCID: 0000-0002-8613-627X.

Page 2 of 5

performed without CPB on a beating heart with the use of mechanical pressure stabilizers. Conventionally, MIDCABs are performed by direct vision, without the use of a scope. However, some modifications of the procedure such as Endoscopic Atraumatic Coronary Artery Bypass (EACAB) and Robotic Assisted Coronary Artery Bypass (RACAB) have been developed, but have not gained widespread adoption. EACAB involves harvest of the LITA with the help of an endoscope and a harmonic scalpel (8), whereas in RACAB the LITA is harvested with robotic assistance that provides high-definition exposure and 3D telemanipulation, which facilitates the harvesting of the LITA without distorting the thorax (9). However, following LITA harvest, a hand-made anastomosis is performed through a small thoracotomy incision similar to that performed during the conventional MIDCAB procedure. The main advantages of using a thoracoscope or robot assistance are lesser chest wall retraction during LITA harvest resulting in lesser postoperative pain, and better visibility and ease of harvesting the LITA, particularly its distal segment, which could be challenging when using direct vision. This translates into less trauma, lower transfusion rates, and faster recovery. An additional benefit of using robotic assistance is the ability to identify the segment of the LAD that is best suitable for performing the anastomosis, thus, helping the surgeon identify the precise site of entry into the thorax (9,10). Conventional MIDCAB procedures have been associated with excellent long-term outcomes (11) and have been shown to be comparable to both conventional CABG and PCI (12,13). EACAB has also been associated with excellent perioperative outcomes, with rates of conversion to sternotomy and LITA injury lower than 1% (8). Similarly, RACAB also provides excellent results with low perioperative mortality and bleeding and acceptable patency rates (14).

MICS-CABG

MICS-CABG, which was described in 2003, is an extension of the MIDCAB procedure that involves multivessel grafting performed through a left antero-lateral thoracotomy, which is performed 2–3 cm more lateral than the MIDCAB incision (12). The feasibility and safety of this procedure have been well-demonstrated (13), and so has its efficacy with respect to patency of grafts (15). The vast majority of the patients received a LITA and vein grafts, with use of radial arteries in some. Most surgeries were performed without CPB, but with partial clamping of the

aorta. The last decade has witnessed further improvisation in MICS-CABG procedures through the use of bilateral ITAs as composite grafts without manipulation of the aorta. Such techniques have gained momentum and are associated with excellent early and mid-term outcomes and graft patency (16). The major advantage of this technique is the complete elimination of sternal wound complications, despite utilization of bilateral ITAs. MICS-CABG is also associated with excellent 10-year survival and freedom from major adverse cardiovascular events (17). Although, a larger number of surgeons are now adopting MICS-CABG procedures, the lack of large randomized trials, structured training programs, increased complexity of these operations and a steep learning curve to achieve expertise have hindered widespread acceptance.

Totally endoscopic coronary artery bypass (TECAB)

First performed by Loulmet and colleagues in 1999 (18), TECAB is the least invasive minimal access CABG procedure that is performed through multiple ports without a surgical incision. One port for the camera and 2 working ports are introduced in the midclavicular/anterior axillary line, through the 2nd, 4th and 6th intercostal spaces. The surgical instruments are introduced through the working ports by the surgical assistant, whereas the surgeon sits at the console and performs the procedure. After conduit harvest, two more ports are added; a subcostal port just lateral to the xiphoid process to introduce the robotic stabilizer (Intuitive da Vinci® Robotic Stabilizer) and another working port in the second intercostal space. Thereafter, the surgeon completes the LITA to LAD anastomosis with robotic surgical instruments or a Flex A distal anastomotic device (Cardica) (19).

TECAB is most beneficial as it eliminates tremors, provides excellent vision and magnification, and avoids a surgical incision, thereby averting rib-spreading and chest distortion. However, TECAB procedures have been limited to few centers worldwide, primarily due to a long learning curve, high costs, complex instrumentation, and lengthy procedural times. TECAB has been associated with a 0.8% operative mortality rate, with a low rate of perioperative complications such as, perioperative stroke (1.5%) and myocardial infarction (2.3%) (20). Additionally, the ITA graft patency is comparable to conventional CABG and is 98.8%, 95.8%, and 93.6% at <1 month, <5 years and >5 years follow-up, respectively (21).

Hybrid coronary revascularization (HCR)

HCR combines the best of both the revascularization techniques, involving MIDCAB and PCI to non-LAD vessels. The sequence of revascularization that is most commonly used is MIDCAB followed by PCI. However, in urgent/emergent situations PCI has to be performed prior to surgery. Occasionally, both procedures are performed simultaneously. It is most beneficial in patients who have a prohibitive risk for conventional CABG or are at a high risk for sternal wound complications. Patients amenable for multivessel PCI receive the long-term survival benefit of the LITA-LAD graft. Nevertheless, this revascularization strategy is limited to only a few centers, as surgeons are not yet convinced of the long-term outcomes due to the paucity of evidence in literature. Very few randomized clinical trials have been performed that demonstrate non-inferiority of HCR to conventional CABG (22). Therefore, HCR is not well represented in the ACC/AHA guidelines on myocardial revascularization (23).

Conclusions and future perspectives

Although stent technology and techniques of PCI have markedly improved over the last 3 decades, conventional CABG continues to be the therapy of choice for treatment of severe multivessel coronary artery disease, particularly in diabetic patients (24). Nonetheless, the demand for PCI and less invasive surgical procedures has increased tremendously over the last 20 years, as it is attractive to patients. Unfortunately, the uptake of minimally invasive CABG is very slow as compared to the increase in PCI procedures. This may be due to the lack of strong evidence to support the use of minimally invasive CABG procedures, the steep learning curve and the very low margin of error associated with these procedures. Hence, there are very few structured training programs in minimally invasive CABG.

It is imperative to conceptualize and conduct adequately powered randomized studies to at least establish noninferiority, if not superiority of minimally invasive over conventional CABG. Currently, the MIST trial, which is a comparison between sternotomy and MICS-CABG for multivessel coronary artery disease, is ongoing (25). Additionally, it is upon the surgeons, who are experts in MICS-CABG, to continue to develop techniques and instrumentation in order to simplify the procedure and shorten the learning curve. It will attract a larger number of surgeons to minimally invasive CABG. The cardiac surgical society should recommend every center to have at least one surgeon in the unit who is competent in minimally invasive CABG. Centers of excellence should establish a structured training program in minimally invasive CABG. Besides, such institutions should also offer peer-to-peer training for surgeons interested in pursuing a career in minimally invasive CABG. Surgeons performing robotic CABG should liaison with industry to develop robots and equipment that would reduce the cost of surgery.

Every institution should adopt the heart team approach involving cardiac surgeons, general and interventional cardiologists in decision-making regarding the appropriate revascularization strategy for every patient, particularly HCR. This would not only optimize the care, but would also increase the confidence of patients in the health care team.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Johan van der Merwe and Filip P. Casselman) for the series "International Perspectives on Minimally Invasive Coronary Artery Revascularization" published in *Journal of Visualized Surgery*. The article has undergone external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jovs. amegroups.org/article/view/10.21037/jovs-22-41/coif). The series "International Perspectives on Minimally Invasive Coronary Artery Revascularization" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the

Page 4 of 5

original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- Benetti FJ, Naselli G, Wood M, et al. Direct myocardial revascularization without extracorporeal circulation. Experience in 700 patients. Chest 1991;100:312-6.
- 2. Sellke FW, Chu LM, Cohn WE. Current state of surgical myocardial revascularization. Circ J 2010;74:1031-7.
- Van den Eynde J, Sá MP, De Groote S, et al. Hybrid coronary revascularization versus percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc 2021;37:100916.
- 4. Lapierre H, Chan V, Sohmer B, et al. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg 2011;40:804-10.
- Marin-Cuartas M, Sá MP, Torregrossa G, et al. Minimally invasive coronary artery surgery: Robotic and nonrobotic minimally invasive direct coronary artery bypass techniques. JTCVS Tech 2021;10:170-7.
- Calafiore AM, Di Giammarco G, Teodori G, et al. Midterm results after minimally invasive coronary surgery (LAST operation). J Thorac Cardiovasc Surg 1998;115:763-71.
- Davierwala PM, Verevkin A, Bergien L, et al. Twentyyear outcomes of minimally invasive direct coronary artery bypass surgery: The Leipzig experience. J Thorac Cardiovasc Surg 2023;165:115-27.e4.
- Abusamra R, Król M, Milewski K, et al. Short and longterm results of endoscopic atraumatic coronary artery off-pump bypass grafting in patients with left anterior descending artery stenosis. Cardiol J 2021;28:86-94.
- Tarola CL, Al-Amodi HA, Balasubramanian S, et al. Ultrafast Track Robotic-Assisted Minimally Invasive Coronary Artery Surgical Revascularization. Innovations (Phila) 2017;12:346-50.
- 10. Currie ME, Romsa J, Fox SA, et al. Long-term angiographic follow-up of robotic-assisted coronary artery revascularization. Ann Thorac Surg 2012;93:1426-31.
- Repossini A, Di Bacco L, Nicoli F, et al. Minimally invasive coronary artery bypass: Twenty-year experience. J Thorac Cardiovasc Surg 2019;158:127-38.e1.
- 12. Srivastava SP, Patel KN, Skantharaja R, et al. Offpump complete revascularization through a left lateral thoracotomy (ThoraCAB): the first 200 cases. Ann Thorac

Surg 2003;76:46-9.

- McGinn JT Jr, Usman S, Lapierre H, et al. Minimally invasive coronary artery bypass grafting: dual-center experience in 450 consecutive patients. Circulation 2009;120:S78-84.
- Giambruno V, Chu MW, Fox S, et al. Robotic-assisted coronary artery bypass surgery: an 18-year single-centre experience. Int J Med Robot 2018;14:e1891.
- Ruel M, Shariff MA, Lapierre H, et al. Results of the Minimally Invasive Coronary Artery Bypass Grafting Angiographic Patency Study. J Thorac Cardiovasc Surg 2014;147:203-8.
- 16. Davierwala PM, Verevkin A, Sgouropoulou S, et al. Minimally invasive coronary bypass surgery with bilateral internal thoracic arteries: Early outcomes and angiographic patency. J Thorac Cardiovasc Surg 2021;162:1109-19.e4.
- Guo MH, Vo TX, Horsthuis K, et al. Durability of Minimally Invasive Coronary Artery Bypass Grafting. J Am Coll Cardiol 2021;78:1390-1.
- Loulmet D, Carpentier A, d'Attellis N, et al. Endoscopic coronary artery bypass grafting with the aid of robotic assisted instruments. J Thorac Cardiovasc Surg 1999;118:4-10.
- Argenziano M, Katz M, Bonatti J, et al. Results of the prospective multicenter trial of robotically assisted totally endoscopic coronary artery bypass grafting. Ann Thorac Surg 2006;81:1666-74; discussion 1674-5.
- 20. Leonard JR, Rahouma M, Abouarab AA, et al. Totally endoscopic coronary artery bypass surgery: A meta-analysis of the current evidence. Int J Cardiol 2018;261:42-6.
- Kitahara H, McCrorey M, Patel B, et al. Benefit of Robotic Beating-Heart Totally Endoscopic Coronary Artery Bypass in Octogenarians. Innovations (Phila) 2019;14:531-6.
- 22. Ganyukov V, Kochergin N, Shilov A, et al. Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS). J Interv Cardiol 2020;2020:5458064.
- Lawton JS, Tamis-Holland JE, Bangalore S, et al.
 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e18-114.
- 24. Farkouh ME, Domanski M, Dangas GD, et al. Long-Term Survival Following Multivessel Revascularization

Journal of Visualized Surgery, 2023

in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol 2019;73:629-38.

25. Guo MH, Wells GA, Glineur D, et al. Minimally Invasive

doi: 10.21037/jovs-22-41

Cite this article as: Fortunato GA, Davierwala PM. The current role and future perspectives of minimally invasive coronary artery bypass grafting. J Vis Surg 2023;9:40.

coronary surgery compared to STernotomy coronary artery bypass grafting: The MIST trial. Contemp Clin Trials 2019;78:140-5.